PlainRecalls
FDA Drug Moderate Class II Completed

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

Reported: October 23, 2024 Initiated: October 10, 2024 #D-0009-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Details

Units Affected
7,107 bottles
Distribution
Product was distributed nationwide within the United States
Location
Berlin, CT

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Distributed by: BPI, NDC 51991-746-05.. Recalled by Breckenridge Pharmaceutical, Inc. Units affected: 7,107 bottles.
Why was this product recalled?
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Which agency issued this recall?
This recall was issued by the FDA Drug on October 23, 2024. Severity: Moderate. Recall number: D-0009-2025.